The global Cabazitaxel market size was valued at US$ 221 million in 2024 and is forecast to a readjusted size of USD 314 million by 2031 with a CAGR of 5.2% during review period.
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
USA is the largest Cabazitaxel market with about 95% market share. Europe is follower, accounting for about 3% market share.The key manufacturers are Sanofi, Tapi Teva, Fuan Pharmaceutical Group, Fujian Yewpark Biological etc. Top 3 companies occupied about 99% market share.
This report is a detailed and comprehensive analysis for global Cabazitaxel market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cabazitaxel market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2020-2031
Global Cabazitaxel market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2020-2031
Global Cabazitaxel market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (USD/g), 2020-2031
Global Cabazitaxel market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (USD/g), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cabazitaxel
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cabazitaxel market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Tapi Teva, Fuan Pharmaceutical Group, Fujian Yewpark Biological, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Cabazitaxel market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Purity above 99%
Other Purity
麻豆原创 segment by Application
Age Below 65
Age Above 65
Major players covered
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cabazitaxel product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cabazitaxel, with price, sales quantity, revenue, and global market share of Cabazitaxel from 2020 to 2025.
Chapter 3, the Cabazitaxel competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cabazitaxel breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Cabazitaxel market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cabazitaxel.
Chapter 14 and 15, to describe Cabazitaxel sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Cabazitaxel Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Purity above 99%
1.3.3 Other Purity
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Cabazitaxel Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Age Below 65
1.4.3 Age Above 65
1.5 Global Cabazitaxel 麻豆原创 Size & Forecast
1.5.1 Global Cabazitaxel Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Cabazitaxel Sales Quantity (2020-2031)
1.5.3 Global Cabazitaxel Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Cabazitaxel Product and Services
2.1.4 Sanofi Cabazitaxel Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Sanofi Recent Developments/Updates
2.2 Tapi Teva
2.2.1 Tapi Teva Details
2.2.2 Tapi Teva Major Business
2.2.3 Tapi Teva Cabazitaxel Product and Services
2.2.4 Tapi Teva Cabazitaxel Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Tapi Teva Recent Developments/Updates
2.3 Fuan Pharmaceutical Group
2.3.1 Fuan Pharmaceutical Group Details
2.3.2 Fuan Pharmaceutical Group Major Business
2.3.3 Fuan Pharmaceutical Group Cabazitaxel Product and Services
2.3.4 Fuan Pharmaceutical Group Cabazitaxel Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Fuan Pharmaceutical Group Recent Developments/Updates
2.4 Fujian Yewpark Biological
2.4.1 Fujian Yewpark Biological Details
2.4.2 Fujian Yewpark Biological Major Business
2.4.3 Fujian Yewpark Biological Cabazitaxel Product and Services
2.4.4 Fujian Yewpark Biological Cabazitaxel Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Fujian Yewpark Biological Recent Developments/Updates
3 Competitive Environment: Cabazitaxel by Manufacturer
3.1 Global Cabazitaxel Sales Quantity by Manufacturer (2020-2025)
3.2 Global Cabazitaxel Revenue by Manufacturer (2020-2025)
3.3 Global Cabazitaxel Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Cabazitaxel by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Cabazitaxel Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Cabazitaxel Manufacturer 麻豆原创 Share in 2024
3.5 Cabazitaxel 麻豆原创: Overall Company Footprint Analysis
3.5.1 Cabazitaxel 麻豆原创: Region Footprint
3.5.2 Cabazitaxel 麻豆原创: Company Product Type Footprint
3.5.3 Cabazitaxel 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cabazitaxel 麻豆原创 Size by Region
4.1.1 Global Cabazitaxel Sales Quantity by Region (2020-2031)
4.1.2 Global Cabazitaxel Consumption Value by Region (2020-2031)
4.1.3 Global Cabazitaxel Average Price by Region (2020-2031)
4.2 North America Cabazitaxel Consumption Value (2020-2031)
4.3 Europe Cabazitaxel Consumption Value (2020-2031)
4.4 Asia-Pacific Cabazitaxel Consumption Value (2020-2031)
4.5 South America Cabazitaxel Consumption Value (2020-2031)
4.6 Middle East & Africa Cabazitaxel Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Cabazitaxel Sales Quantity by Type (2020-2031)
5.2 Global Cabazitaxel Consumption Value by Type (2020-2031)
5.3 Global Cabazitaxel Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Cabazitaxel Sales Quantity by Application (2020-2031)
6.2 Global Cabazitaxel Consumption Value by Application (2020-2031)
6.3 Global Cabazitaxel Average Price by Application (2020-2031)
7 North America
7.1 North America Cabazitaxel Sales Quantity by Type (2020-2031)
7.2 North America Cabazitaxel Sales Quantity by Application (2020-2031)
7.3 North America Cabazitaxel 麻豆原创 Size by Country
7.3.1 North America Cabazitaxel Sales Quantity by Country (2020-2031)
7.3.2 North America Cabazitaxel Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Cabazitaxel Sales Quantity by Type (2020-2031)
8.2 Europe Cabazitaxel Sales Quantity by Application (2020-2031)
8.3 Europe Cabazitaxel 麻豆原创 Size by Country
8.3.1 Europe Cabazitaxel Sales Quantity by Country (2020-2031)
8.3.2 Europe Cabazitaxel Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Cabazitaxel Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Cabazitaxel Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Cabazitaxel 麻豆原创 Size by Region
9.3.1 Asia-Pacific Cabazitaxel Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Cabazitaxel Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Cabazitaxel Sales Quantity by Type (2020-2031)
10.2 South America Cabazitaxel Sales Quantity by Application (2020-2031)
10.3 South America Cabazitaxel 麻豆原创 Size by Country
10.3.1 South America Cabazitaxel Sales Quantity by Country (2020-2031)
10.3.2 South America Cabazitaxel Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Cabazitaxel Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Cabazitaxel Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Cabazitaxel 麻豆原创 Size by Country
11.3.1 Middle East & Africa Cabazitaxel Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Cabazitaxel Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Cabazitaxel 麻豆原创 Drivers
12.2 Cabazitaxel 麻豆原创 Restraints
12.3 Cabazitaxel Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Cabazitaxel and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cabazitaxel
13.3 Cabazitaxel Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cabazitaxel Typical Distributors
14.3 Cabazitaxel Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Sanofi
Tapi Teva
Fuan Pharmaceutical Group
Fujian Yewpark Biological
听
听
*If Applicable.
